



TRANSVAC

European Vaccine Research & Development Infrastructure

TRANSVAC2: Improving and accelerating vaccine development in Europe

Stefan Jungbluth, PhD MBA

Head of Business Development

European Vaccine Initiative (EVI)

stefan.jungbluth@euvaccine.eu



European
Commission

Horizon 2020
European Union funding
for Research & Innovation



EUROPEAN VACCINE INITIATIVE

About EVI

- Non-profit organisation supporting the development of vaccines for Global Health
- Established in 1998, based in Germany
- Coordinator of TRANSVAC since its beginning in 2009

Today's Catalyst For Tomorrow's Vaccines



TRANSVAC

European Vaccine Research & Development Infrastructure

TRANSVAC aims to accelerate vaccine development by enhancing European vaccine R&D and training, and increase sustainability of vaccine projects by implementing a permanent research infrastructure for early vaccine development.



TRANSVAC

European Vaccine Research & Development Infrastructure

EU-funded infrastructure project

Provide to the vaccine R&D community:

- State-of-the-art scientific-technical vaccine development services
- Technical training
- Innovative vaccine research and development (R&D)



TRANSVAC

European Vaccine Research & Development Infrastructure

EC Infrastructure Project:

26 partners | 9 countries | 5 years | € 13M

Extra funding received for COVID-19 vaccines

TRANSVAC2 Partners



TRANSVAC2: New vaccines faster... How?



Support innovation and development of **human** and **veterinary**, **prophylactic** and **therapeutic** vaccines



Accelerate vaccine development by developing & applying cutting-edge technologies




Offer training courses to provide fundamental and advanced knowledge in vaccinology



Develop a sustainable vaccine infrastructure accelerating vaccine R&D

TRANSVAC2: Activities




TRANSVAC2: Trans-National Access (TNA) Services

- Services organised in four platforms:
 - Technology
 - Immunocorrelates & Systems Biology
 - Animal Models
 - Clinical Support
- Supports [preclinical and clinical vaccine](#) development
- Services and expertise provided by [TRANSVAC2 partners](#)
- [Free-of-charge](#) (with few exceptions)
- Services from few [weeks](#) to several [months](#)



TNA Services, across the R&D Pipeline



TECHNOLOGY

- TNA1 Cross-platform screening and optimization service
- TNA 2 Adjuvants and delivery systems
- TNA 3 Analytical services
- TNA 4 Pre-clinical GLP production
- TNA 5 GMP production
- TNA 6 Structural Biology

TNA 7 IMMUNOCORRELATES AND SYSTEMS BIOLOGY

TNA 8 ANIMAL MODELS

TNA 9 CLINICAL SUPPORT

Regulatory support

TNA Services: Who can apply?

- Public institutions, SMEs & industry
- Majority of Users **MUST** work in an institution established in **an EU Member State or Associated State**
- **BUT:** also open for researchers from other non-EU countries (up to 20% of a specific services)
- Users **MUST** work in a **different country than the TRANSVAC Service provider**
- Users **MUST openly disseminate** the results generated with the support of TRANSVAC2.

Applicants are encouraged to follow an integrated approach by applying for complementing services.

TNA Services: Who can apply?

- Public institutions, SMEs & industry
- Majority of Users **MUST** work in an institution established in an EU Member State or Associated State
- **BUT**: also open for researchers from other non-EU countries (up to 20% of a specific services)
- Users **MUST** work in a different country than the TRANSVAC Service provider
- Users **MUST** openly disseminate the results generated with the support of TRANSVAC2.

Applicants are encouraged to follow an integrated approach by applying for complementing services.

TNA Services: Who can apply?

- For further details re how to apply, deadlines etc: please see:

www.transvac.org

- Next application cut-off date:

15 April 2021

(call opens 15 Feb 2021)

TRANSVAC2 Training Modules

M1

Clinical vaccine development and biomanufacturing

M2

Human and Veterinary vaccine development

M3

Adjuvants and Vaccine Formulation

M4

Validity and comparison of animal models

M5

Statistics for Vaccine Evaluation

M6

Cytometry by time-of-flight (CyTOF)

M7

Flow cytometry

M8

In vivo Imaging

M9

Process Development and scale-up of viral vaccines

M10

Assay Development and Validation (SPR Technologies)

M11

Process development and scale-up of recombinant

M12

Requirements for GMP production

M13

Systems biology of vaccinology

M14

Regulatory aspects of vaccine development

TRANSVAC2: New vaccines faster

TRANSVAC2's comprehensive approach catalyses optimization, sustainability and harmonization of the vaccine development workflow by driving Europe's capacity in vaccinology (trainings) and providing high-value scientific and technical support services (TNA).



“ TRANSVAC2, supporting the present and transforming the future of vaccine R&D landscape in Europe, while creating global (health) impact.”



TRANSVAC

Thank you

Find out more at www.transvac.org

Contact us:

transvacinfo@euvaccine.eu

stefan.jungbluth@euvaccine.eu

Follow European Vaccine Initiative



European
Commission

Horizon 2020
European Union funding
for Research & Innovation

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.